SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.

Shenzhen New Industries Biomedical Engineering Co., Ltd.

Equities

300832

CNE100003T39

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
70.15 ^CNY	+2.56%		+8.46%	-10.29%

Apr. 26	Nomura Adjusts Shenzhen New Industries Biomedical Engineering’s Price Target to 93.36 Yuan From 98.15 Yuan, Keeps at Buy	MT
Apr. 25	Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Shenzhen New Industries Biomedical Engineering Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 08 June 2023

June 02, 2023 at 03:33 pm EDT

Shenzhen New Industries Biomedical Engineering Co., Ltd. announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 7.00000000 for the year 2022, payable on 08 June 2023. Record date is 07 June 2023. Ex-date is 08 June 2023.

Latest news about Shenzhen New Industries Biomedical Engineering Co., Ltd.

Nomura Adjusts Shenzhen New Industries Biomedical Engineering’s Price Target to 93.36 Yuan From 98.15 Yuan, Keeps at Buy	Apr. 26	MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Shenzhen New Industries Biomedical Engineering Gets Nod to Register Five Devices	Apr. 18	MT
Shenzhen New Industries Biomedical Engineering's 2023 Profit Jumps 25%	Apr. 11	MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 11	CI
Nomura Adjusts New Industries Biomedical Engineering’s Price Target to 98.15 Yuan From 86.13 Yuan, Keeps at Buy	Mar. 12	MT
Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 86.13 Yuan From 75.19 Yuan, Keeps at Buy	Dec. 18	MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 75.19 Yuan From 71.58 Yuan, Keeps at Buy	23-10-13	MT
Shenzhen New Industries' Profit Jumps 32% in H1	23-08-25	MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Nomura Adjusts Shenzhen New Industries Biomedical Engineering’s Price Target to 71.58 Yuan From 69.88 Yuan, Keeps at Buy	23-07-19	MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 08 June 2023	23-06-02	CI
Shenzhen New Industries Biomedical Engineering's Shareholders Plan To Unload Company Stakes	23-05-28	CI
Certain A Shares of Shenzhen New Industries Biomedical Engineering Co., Ltd. are subject to a Lock-Up Agreement Ending on 12-MAY-2023.	23-05-11	CI
Nomura Adjusts New Industries Biomedical's Price Target to 69.88 Yuan From 71.05 Yuan, Keeps at Buy	23-04-28	MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Shenzhen New Industries Biomedical Engineering Co., Ltd. Announces Profit Distribution Proposal for 2022	23-04-07	CI
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-06	CI
Nomura Adjusts Shenzhen New Industries Biomedical Engineering’s Price Target to 71.05 Yuan From 67.87 Yuan, Keeps at Buy	23-02-28	MT
Shenzhen Yinghe Brain Science Co., Ltd announced that it has received $14.800000 million in funding from Eli Lilly Investment Consulting Shanghai Co., Ltd., Shenzhen New Industries Biomedical Engineering Co., Ltd., Beijing Enlight Media Co., Ltd., Xi'an Xijiao 1896 Capital Management Co., Ltd., Shenzhen Qianhai BangQin Investment Co., Ltd. and other investors.	23-01-29	CI
Shenzhen New Industries Receives Provincial Registration Certificate for Parathyroid Hormone Kit	22-11-07	MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-20	CI
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Shenzhen New Industries Biomedical Engineering Co., Ltd. Implements Final Cash Dividend for 2021, Payable on 23 June 2022	22-06-17	CI

Chart Shenzhen New Industries Biomedical Engineering Co., Ltd.

Duration

Period

Chart Shenzhen New Industries Biomedical Engineering Co., Ltd.

More charts

Company Profile

Shenzhen New Industries Biomedical Engineering Co Ltd is a company engaged in research and development, production and sales of in-vitro diagnostics instruments and supporting reagents. The Company operates three segments, including Instruments and Supporting Software, Reagents, Accessories and Others. Instruments and Supporting Software segment is involved in the production and sales of MAGLUMI automatic chemiluminescence immunoassay analyzer series products and Biossays automatic biochemical analyzer series products. Reagents segment operates the sales of supporting reagents for the analyzers. The products are applied in the examination of Gonads, thyroid gland, glucose metabolism, kidney function and so on. Accessories and Others segment is responsible for the manufacturing and sales of accessories related to in-vitro diagnostics equipment. The Company sells its products both in domestic and international markets, including Asia, Europe, America and Africa.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-06 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Shenzhen New Industries Biomedical Engineering Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

70.15 CNY

Average target price

80.56 CNY

Spread / Average Target

+14.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-10.29%	7.61B
BIOMÉRIEUX	+0.89%	12.8B
DIASORIN S.P.A.	+1.78%	5.41B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.16%	4.51B
LANTHEUS HOLDINGS, INC.	+5.74%	4.49B
10X GENOMICS, INC.	-50.70%	3.29B
ANDON HEALTH CO., LTD.	+12.21%	2.73B
VITROLIFE AB	-16.13%	2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.50%	1.73B
MYRIAD GENETICS, INC.	-5.02%	1.64B

Diagnostic & Testing Substances